Last updated: May 26, 2026
Butalbital, Acetaminophen and Caffeine Suppliers: API, Finished Dosage, and Distribution Options for Combination Products
The combination of butalbital, acetaminophen, and caffeine is supplied through (1) branded and generic finished-dose manufacturers, (2) API and intermediate suppliers, and (3) contract manufacturers that produce tablets for relabelers and distributors. Supply is typically structured around existing, FDA-listed finished-dose partners and vertically integrated or long-standing API vendors, because regulatory and quality-system requirements restrict interchangeable sourcing.
This page maps supplier categories and the practical procurement paths used in the US market for butalbital/acetaminophen/caffeine products.
What companies supply butalbital, acetaminophen, and caffeine finished tablets in the US?
Direct finished-dose suppliers dominate procurement for US commercial supply, because manufacturers must be FDA-registered, comply with cGMP, and hold the ANDA/label approvals (for generics) or NDA labeling (for branded).
Common sourcing routes used by buyers
- US generic finished-dose manufacturers (ANDA holders)
Buyers contract with the approved generic manufacturer or purchase through their authorized distributor network.
- Branded-label manufacturers
Buyers typically source through wholesaler channels that stock the branded product.
- Contract manufacturing (CMO) with finished-dose approvals
In some cases, the buyer sources via a CMO, but the marketing authorization still sits with a US label holder.
What this means for supplier selection
For butalbital/acetaminophen/caffeine, supplier qualification usually requires:
- Confirmation of ANDA or NDA labeling coverage for the exact strength (mg dosing) and dosage form (tablets).
- Evidence of batch release testing and supplier change control.
- Verification of DEA controlled substance handling for butalbital content (even though butalbital is not a controlled substance for all regulatory contexts, the product supply chain in practice is treated with heightened compliance).
Who are the API suppliers for butalbital, acetaminophen, and caffeine?
API sourcing is split by chemical class.
Butalbital API suppliers
Butalbital (CAS 57-85-2) is usually supplied by:
- Specialty chemical API producers
- Multi-product generic API plants with controlled substance supply-chain controls
- International API manufacturers that support DMF-driven qualification
Acetaminophen API suppliers
Acetaminophen (CAS 103-90-2) is a high-volume commodity API with many global suppliers. Buyers usually have more flexibility on acetaminophen sourcing than on butalbital.
Caffeine API suppliers
Caffeine (CAS 58-08-2) also has multiple global suppliers. The limiting factor is less caffeine and more integration with the specific combination product formulation and release testing.
How do manufacturers qualify suppliers for the butalbital/acetaminophen/caffeine combination?
Supplier qualification follows cGMP expectations and quality-by-design procurement norms.
Typical qualification requirements
- CoA and specification alignment for each API grade
- DMF cross-reference (or equivalent documentation) for API used in marketed formulations
- Change control acceptance for:
- API supplier
- impurity profile
- polymorphic form where relevant (less common for these APIs than for complex APIs, but still assessed)
- Stability data for the combination product using the qualified API grade
Which raw-material intermediates affect supply for butalbital combination products?
For this combination, supply disruption often comes from intermediates tied to:
- Butalbital synthesis (key intermediates can be capacity-constrained)
- Acetaminophen grade selection (particle size and impurity profile consistency)
- Caffeine extraction/grade (food/pharma grade sourcing differences can affect impurity specifications)
In procurement practice, buyers often lock multiple backup vendors for each upstream input, then validate the combination product batch performance.
What are the DEA and controlled-substance compliance impacts on supplier selection?
Butalbital-containing combination drugs sit in a compliance-heavy category. Even when the API itself is not always treated the same as Schedule II substances in all contexts, the finished-dose distribution chain is typically subject to heightened controls.
Procurement and distribution planning typically require suppliers to support:
- secure storage and handling processes
- compliant shipping documentation
- audited logistics and traceability
What generic manufacturers sell butalbital, acetaminophen and caffeine tablets in the US?
This combination is marketed widely as generic tablets at common strengths (notably 50 mg butalbital / 300 mg acetaminophen / 40 mg caffeine per tablet, depending on label). Generic supply is usually handled through:
- ANDA-approved tablet manufacturers
- national distributors serving retail and institutional channels
Supplier identification in the US typically starts with the Orange Book listing for the exact strength, then confirms:
- the ANDA holder
- patent/Exclusivity entries
- authorized distribution status
What FDA regulatory status and Orange Book listings control supplier availability?
For finished-dose supplier viability, the critical constraints are:
- which ANDAs are approved for the exact dosage form and strength
- whether exclusivities delay generic entry
- whether relevant patents are listed and actively enforced
Why this matters for procurement
If only a small number of ANDA holders are active for the exact strength, supply depends on those limited manufacturers and their upstream API availability.
Which supplier risks drive shortages for this combination?
Supply risk is usually concentrated in:
- Butalbital API production capacity
Upstream constraints can cascade into finished-dose scarcity.
- Quality deviation risk
Failure to meet impurity specifications can force batch holds.
- Regulatory and compliance friction
Transport and secure handling failures can cause delays.
- CMO capacity churn
Contract manufacturers may switch site production, changing timelines.
How do ingredient sourcing strategies differ between branded and generic suppliers?
Branded-label strategies
- More conservative multi-sourcing for butalbital API
- Longer forecasting horizons
- Contracted supply with change control lock-ins
Generic strategies
- Higher emphasis on cost and batch economics
- More active supplier-switching, but only after regulatory and quality validation
What manufacturing/IP barriers affect upstream and CMO sourcing?
Barrier types that affect supplier switching include:
- Formulation-specific processing and granulation methods
- quality system lock-in for impurity control
- data package dependence when approvals rely on specific API grade and impurity profiles
- DMF dependence for butalbital API qualification
Supplier matrix for butalbital/acetaminophen/caffeine: what to request in diligence
| Category |
What to ask |
Why it matters |
| Finished-dose manufacturer |
ANDA/NDA label confirmation by strength and NDC |
Prevents procurement mismatch |
| API vendor |
API grade/spec, impurity profile, DMF status |
Enables regulatory comparability |
| CMO |
Batch size, site history, change-control willingness |
Reduces timeline and risk |
| Logistics/distribution |
Secure handling and documentation |
Prevents compliance delays |
| Testing lab |
Release and stability test capability |
Avoids batch holds |
Key Takeaways
- Finished-dose suppliers for butalbital/acetaminophen/caffeine are usually the fastest route to reliable supply because they already hold the FDA authorization and cGMP package.
- API sourcing is constrained most by butalbital upstream capacity and impurity control, with more flexibility for acetaminophen and caffeine.
- Compliance-heavy handling requirements for butalbital-containing products shape qualification and logistics more than standard commodity drugs.
- Procurement reliability depends on securing multiple qualified upstream vendors and validating change control pathways for API grade substitutions.
FAQs
1) How do I identify the real-world suppliers for butalbital/acetaminophen/caffeine tablets?
Use the FDA Orange Book listing for the exact strength and dosage form, then map the ANDA holder(s) to current distributors and authorized wholesalers stocking the relevant NDCs.
2) Is butalbital API harder to source than acetaminophen or caffeine?
In practice, yes. Procurement variability typically tracks capacity and impurity control constraints that are most acute for butalbital.
3) What documentation is usually required from an API supplier for qualification?
CoA/spec alignment, impurity profile support, and regulatory dossier linkage (DMF or equivalent referenced documentation).
4) Can a buyer switch API suppliers without regulatory impact?
Usually not without change control and comparability evidence at the finished-dose level. The practical path is qualification plus regulatory assessment.
5) What causes more shortages: API or finished-dose manufacturing?
For this combination, upstream API constraints and batch release holds commonly drive shortages more than packaging logistics.
References (APA)
No sources were cited.
